160 Data are presented as proportions n with corresponding percentages (%) or as median [interquartile range, IQR] in case of continuous variables. Abbreviations: CD, Crohn’s disease; HC, healthy control; IBD, inflammatory bowel disease; IBD-U, inflammatory bowel disease unclassified; TNF, tumor necrosis factor; UC, ulcerative colitis. disease (P), CD 3 (8.8%) - Montreal Extension (E), UC E1 (proctitis) 3 (17.6%) - E2 (left-sided colitis) 4 (23.5%) - E3 (pancolitis) 10 (58.8%) - Montreal Severity (S), UC S0 (remission) 4 (23.5%) - S1 (mild) 4 (23.5%) - S2 (moderate) 3 (17.6%) - S3 (severe) 5 (29.4%) - Medication use Aminosalicylates, n (%) 20 (36.3%) - Steroids, n (%) 11 (20.0%) - Immunosuppressives, n (%) 26 (47.2%) - TNF-antagonists, n (%) 14 (25.5%) - Disease activity Remission, n (%) 42 (76.4%) - Active disease, n (%) 13 (23.6%) - Surgical history Ileostomy/pouch, n (%) 7 (12.7%) - Data are presented as proportions n with corresponding percentages (%) or as median [interquartile range, IQR] in case of continuous variables. Abbreviations: CD, Crohn’s disease; HC, healthy contr l; IBD, inflamm tory bowel disease; IBD-U, inflammatory bowel disease unclassified; TNF, tumor necrosis factor; UC, ulcerative colitis. Chapter 5
RkJQdWJsaXNoZXIy MjY0ODMw